This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
Not reported. The author directed the reader to a website for a detailed description of the methods, but the URL for this site was no longer valid.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The values for the parameters in the model were obtained from three published studies, statistics from a government website and the unpublished results of a survey.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The results for most parameters were expressed as point estimates with a range: go to a physician or clinic, 45.30% (range: 11.30 -79.30 
Measure of benefits used in the economic analysis
The authors did not develop a summary benefit measure for the economic analysis. Although the number of avoided pregnancies was the principal outcome produced with the model, this was not synthesised with the costs. The study can therefore be considered a cost-consequences analysis.
Direct costs
The risk parameters and the costs entered in the model were reported separately. Both patient and public payer perspectives were considered in the analysis. The costs included were nausea, ECP pharmacy costs, ECP physician costs and unintended pregnancy costs (i.e. induced abortion, spontaneous abortion, ectopic pregnancy and birth). The cost data were obtained from electronic and published sources from 1995 to 1999 and were adjusted to a 1998 price year. Discounting was, appropriately, not applied as the timeframe was only 9 months. The average costs were reported.
Statistical analysis of costs
Point estimates and a range of values were presented. No statistical analysis of the costs was reported.
Indirect Costs
The indirect costs were not included.
Currency

US dollars ($).
Sensitivity analysis
A sensitivity analysis was undertaken on all parameters and costs used in the model to investigate variability in the data. The ranges of values used were taken from published sources or, if unavailable, the point estimate was generally varied by 25%. Probabilistic and multivariate sensitivity analyses were undertaken using Monte Carlo simulation, assigning a normal distribution to the costs and a logistic-normal distribution for the risks.
Estimated benefits used in the economic analysis
The incidence of pregnancy was 1.8% for ECP provided by the pharmacy and 4.9% for ECP obtained from a physician. The absolute difference was 3.1% (95% confidence interval, CI: 1.1 -5.3%). The other outcomes are reported in the "Results of the Review" section.
Cost results
From the perspective of a private payer, obtaining ECP from a pharmacy resulted in a $158 (95% CI: 76 -269) reduction in the cost per woman having unprotected sex. From the perspective of a public payer, this reduction in cost was $48 (95% CI: 16 -93) per woman.
Synthesis of costs and benefits
Not applicable.
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